



CARDIOMEMS™ HF SYSTEM

PATIENT CANDIDATE CONSIDERATIONS

THE CARDIOMEMS™ HF SYSTEM IS INDICATED FOR THESE PATIENTS¹:

- NYHA Class III heart failure
- One heart failure hospitalization in the past 12 months

Note: A typical NYHA Class III heart failure patient has marked limitation of physical activity. Less than ordinary activity leads to symptoms (moderate congestive heart failure). Doctors commonly look at a Class III patient's heart failure symptoms in the last 30 days.

THE CARDIOMEMS HF SYSTEM IS CONTRAINDICATED FOR THESE PATIENTS:

- Patients with an inability to take dual antiplatelet or anticoagulants for one month post implant

PATIENTS WHO MOST COMMONLY RECEIVE THE CARDIOMEMS HF SYSTEM ARE THOSE ON GDMT AND THOSE WHO EXHIBIT ANY OF THE FOLLOWING¹:

- Fluid volumes are hard to know or manage
- Physical assessment is challenging
- Is a patient with HFpEF or HFrEF
- Compliant with heart failure medical care
- Would benefit from remote monitoring if they live far from a clinic

Note: The CHAMPION trial specifically excluded patients with American College of Cardiology/American Heart Association stage D heart failure who needed advanced therapies (i.e., left ventricular assist device, transplant or inotropic support). Even if inotropic support improved heart failure symptoms, a patient would still be defined as stage D, with refractory heart failure.¹

Medical care of the patient is the sole responsibility of the acting practitioner. This document is not intended to replace the judgment of the acting practitioner nor the establishment of final protocols within the hospital setting. It does not represent any opinion or endorsement by Abbott of any particular approach to patient management or treatment.



TAKE THE GUESSWORK OUT OF HEART FAILURE MANAGEMENT

PROACTIVELY MANAGE HEART FAILURE

Pulmonary artery pressure management allows proactive and personalized heart failure management for your patients, with pressure-guided medication intervention.

IMPROVE QUALITY OF LIFE (QOL)

Give your patients significant improvements in QOL, compared with standard of care heart failure management.

- 9-pt difference in MLHFQ²
- Improved exercise capacity³

REDUCE HEART FAILURE HOSPITALIZATIONS

The CardioMEMS™ HF System is more effective in reducing heart failure hospitalizations than signs/symptoms alone.⁴

- Heart failure hospitalizations ↓33%²
- All-cause 30-day readmissions ↓58%^{5*}

HELP YOUR HFpEF PATIENTS

Provide your preserved EF patients with the CardioMEMS HF System, and significantly reduce their hospitalization risk.

- The CardioMEMS HF System is the first and only device that has shown improvement in this patient population.
- HFpEF heart failure hospitalizations ↓50%^{6*}

*Retrospective analysis from the CHAMPION Trial.

1. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. *The Lancet*. 2011;377(9766):658-666.
2. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *The Lancet*. 2016;387(10017):453-461.
3. Alam A, Jermyn R, Joseph M, Patel S, Jorde U, Saeed O. Improved quality of life scores and exercise capacity with remote pulmonary artery pressure monitoring in patients with chronic heart failure. *Journal of the American College of Cardiology*. 2016;67(13):1299.
4. Costanzo MR, Stevenson LW, Adamson PB, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. *Journal of the American College of Cardiology: Heart Failure*. 2016;4(5):333-344.
5. Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. *Circulation: Heart Failure*. 2016;7:935-944.
6. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circulation: Heart Failure*. 2014;7(6):935-944.

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA
Tel: 1 651 756 2000
Abbott.com

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

™ Indicates a trademark of the Abbott group of companies.

© 2019 Abbott. All Rights Reserved.

28980-SJM-MEM-0617-0336(2) | Item approved for U.S. use only.

